Related Experiment Video

Updated: Jun 7, 2026

The Antihypertensive Effects and Mechanisms of Huotan Jiedu Tongluo Decoction in Rats with H-Type Hypertension
05:57

The Antihypertensive Effects and Mechanisms of Huotan Jiedu Tongluo Decoction in Rats with H-Type Hypertension

Published on: May 17, 2024

Are there benefits of antihypertensive therapy beyond blood pressure lowering?

Joseph L Izzo1

  • 1Erie County Medical Center, State University of New York at Buffalo, 462 Grider Street, Buffalo, NY 14215, USA. jizzo@buffalo.edu

Current Hypertension Reports
|October 28, 2010
PubMed

Insights

Lowering blood pressure (BP) is key for preventing cardiovascular events. However, the best drug choice depends on individual patient health, especially with comorbidities.

Area of Science:

  • Cardiovascular Medicine
  • Clinical Pharmacology

Background:

  • Antihypertensive therapy's primary benefit in uncomplicated individuals stems from reduced blood pressure (BP), not specific drug classes.
  • Comorbidities significantly influence therapeutic benefit, necessitating careful drug selection based on the patient's health profile.

Purpose of the Study:

  • To analyze the impact of drug class selection versus BP reduction on therapeutic outcomes.
  • To explore the complexities and uncertainties arising from progressively lower BP targets in hypertension management.

Main Methods:

  • Review of meta-analyses and clinical trial data on antihypertensive therapies.
  • Analysis of the BP-risk relationship and its geometric nature.
  • Examination of factors contributing to conflicting trial results, including comorbidities and study design limitations.

Main Results:

  • The choice of antihypertensive agent is secondary to BP reduction in uncomplicated hypertension.
  • Drug class appropriateness is paramount when comorbidities are present.
  • Conflicting results in trials are attributed to various factors like confounding, interactions, and study design flaws.

Conclusions:

  • While BP reduction is crucial in most clinical scenarios, no single antihypertensive drug class is universally superior due to clinical heterogeneity.
  • Tailoring therapy based on individual comorbidity profiles is essential for optimizing treatment outcomes.

Related Concept Videos

Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Antihypertensive Drugs: Action of Diuretics01:16

Antihypertensive Drugs: Action of Diuretics

Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various tubules...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...